Effects of protease therapy in the remnant kidney model of progressive renal failure

Mineral and Electrolyte Metabolism

Volumn 23, Issue 3-6, 1997, Pages 291-295

  Sebekova, K ^a   Paczek, L ^b   Dammrich J ^d   Ling, H ^d   Spustova, V ^a   Gaciong, Z ^b   Heidland, A ^c  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d NONE

Author keywords

Interstitial fibrosis; Proteases; Remnant kidney

Indexed keywords

BROMELAIN; CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CYTOKINE; PHLOGENZYM; PROTEINASE; RUTOSIDE; TRANSFORMING GROWTH FACTOR BETA; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; FIBROSING ALVEOLITIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD PRESSURE; BROMELAINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG COMBINATIONS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; NEPHRECTOMY; RATS; RATS, WISTAR; RUTIN; TRYPSIN;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0030657987     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Lovett DH, Sterzel RB, Kashgarian M, Ryan JL: Neutral proteinase activities produced in vitro by cells of the glotmerular mesangium. Kidney Int 1983;23:342-349.
2. Davies M, Martin J, Thomas GJ, Lovett DH: Proteinases and glomerular matrix turnover. Kidney Int 1992;41:671-678.
3. Heidland A, Ling H, Vamvakas S, Paczek L: Impaired proteolytic activity as a potential cause of progressive renal disease. Miner Electrolyte Metab 1996;22:157-161.
4. Teschner M, Schaefer RM, Svarnas A, Heidland U, Heidland A: Decreased proteinase activity in isolated glomeruli of streptozotocin diabetic rats. Am J Nephrol 1989;9:464-469.
5. Paczek L, Teschner M, Schaefer RM, Kovar J, Romen W, Heidland A: Intraglomerular proteinase activity in adriamycin-induced nephropathy. Nephron 1992;60:81-86.
6. Olbricht CJ, Geissinger B: Renal hypertrophy in streptozotocin diabetic rats: Role of proteolytic enzymes. Kidney Int 1992;41:966-972.
7. Reckelhoff JF, Tygart VL, Mitias MM, Walcott JL: STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloproteinase in rats. Diabetes 1993;42:1425-1432.
8. Shechter P, Boner G, Rabkin R: Tubular cell protein degradation in early diabetic renal hypertrophy. J Am Soc Nephrol 1984;4:1582-1587.
9. Schaefer L, Lorenz T, Daemmrich J, Heidland A, Schaefer RM: Role of proteinases in renal hypertrophy and matrix accumulation. Nephrol Dial Transplant 1995;10:801-807.
10. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42:1462-1469.
11. Feng I, Tang WW, Loskutoff DJ, Wilson CB: Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol 1993;3:1753-1764.
12. Baricos WH: Decreased proteolysis of the glomerular extracellular matrix as a pathogenetic mechanism in progressive renal disease. J Nephrol 1994;7:322-328.
13. Nakazawa M, Emancipator SN, Lamm ME: Removal of glomerular immune complexes in passive serum thickness nephritis by treatment in vivo with proteolytic enzymes. Lab Invest 1986;55:551-556.
14. White RB, Lowrie L, Stork LE, Iskander SS, Lamm ME, Emancipator SN: Targeted enzyme therapy of experimental glomerulonephritis in rats. J Clin Invest 1991;87:1819-1827.
15. Gaciong Z, Paczek L, Bojakowski K, Socha K, Wisniewski M, Heidland A: Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrol Dial Transplant 1996;11:987-989.
16. Morrison AB: Experimentally induced chronic renal insufficiency in the rat. Lab Invest 1962;11:321-332.
17. Spiro RG: Studies on the renal glomerular basement membrane: Preparation and chemical composition. J Biol Chem 1984;242:1915-1919.
18. Smith PK, Krohn RJ, Hermanson GT, Mallia AK, Garter FH, Provenzano M, Fujmoto EK, Goeke NM, Oison BJ, Klenk DC: Measurement of protein using bicinochinic acid. Anal Biochem 1985;150:76-85.
19. Labarca C, Peigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1979;102:344-352.
20. Barrett AJ, Kirschke H: Cathepsin B, cathepsin H and cathepsin L. Methods Enzymol 1981;80:535-540.
21. Edwards DR, Murphy G, Reynolds JJ, Whitman SE, Docherty AJP, Angel P, Heath JK: TGF-β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-1904.
22. 1, on cathepsin activity in cultured tubule cells. Am J Physiol 1995;269: F911-F917.
23. 1, in disease: The dark side of tissue repair. J Clin Invest 1992;90:1-7.
24. 2M. Ann NY Acad Sci 1994;737:245-262.
25. 2-Macroglobulin, a multifunctional binding protein with targeting characteristic. FASEB J 1992;6:3345-3353.
26. 2macroglobulin. Immunol Today 1990;11:163-166.
27. 1 in mice. J Clin Invest 1991;87:39-44.
28. 2M-trypsin complexes. J Immunol 1986;136:2792-2799.
29. Lehmann PV: Immunomodulation by proteolytic enzymes. Nephrol Dial Transplant 1996;11:953-955.
30. Harrach T, Gebauer F, Eckert K, Kunze R, Maurer HR: Bromelain proteinases modulate the CD44 expression on Molt 4/8 leukemia and SK-Mel 28 melanoma cells in vitro. Int J Oncol 1994;5:485-488.
31. Jones CI, Forbes JM, Walker RG, Becker GJ: Activation of renal type IV collagenases. J Am Soc Nephrol 1996;7:2549A.